Titre : Composés de pyridinium

Composés de pyridinium : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cognitive Dysfunction
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Composés de pyridinium : Questions médicales les plus fréquentes", "headline": "Composés de pyridinium : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Composés de pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-05", "dateModified": "2025-03-31", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Composés de pyridinium" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Pyridines", "url": "https://questionsmedicales.fr/mesh/D011725", "about": { "@type": "MedicalCondition", "name": "Pyridines", "code": { "@type": "MedicalCode", "code": "D011725", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cétylpyridinium", "alternateName": "Cetylpyridinium", "url": "https://questionsmedicales.fr/mesh/D002594", "about": { "@type": "MedicalCondition", "name": "Cétylpyridinium", "code": { "@type": "MedicalCode", "code": "D002594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.232" } } }, { "@type": "MedicalWebPage", "name": "Diquat", "alternateName": "Diquat", "url": "https://questionsmedicales.fr/mesh/D004178", "about": { "@type": "MedicalCondition", "name": "Diquat", "code": { "@type": "MedicalCode", "code": "D004178", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.352" } } }, { "@type": "MedicalWebPage", "name": "1-Méthyl-4-phényl-pyridinium", "alternateName": "1-Methyl-4-phenylpyridinium", "url": "https://questionsmedicales.fr/mesh/D015655", "about": { "@type": "MedicalCondition", "name": "1-Méthyl-4-phényl-pyridinium", "code": { "@type": "MedicalCode", "code": "D015655", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.550" } } }, { "@type": "MedicalWebPage", "name": "Chlorure d'obidoxime", "alternateName": "Obidoxime Chloride", "url": "https://questionsmedicales.fr/mesh/D009768", "about": { "@type": "MedicalCondition", "name": "Chlorure d'obidoxime", "code": { "@type": "MedicalCode", "code": "D009768", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.600" } } }, { "@type": "MedicalWebPage", "name": "Paraquat", "alternateName": "Paraquat", "url": "https://questionsmedicales.fr/mesh/D010269", "about": { "@type": "MedicalCondition", "name": "Paraquat", "code": { "@type": "MedicalCode", "code": "D010269", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.621" } } }, { "@type": "MedicalWebPage", "name": "Bromure de pyridostigmine", "alternateName": "Pyridostigmine Bromide", "url": "https://questionsmedicales.fr/mesh/D011729", "about": { "@type": "MedicalCondition", "name": "Bromure de pyridostigmine", "code": { "@type": "MedicalCode", "code": "D011729", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.740" } } }, { "@type": "MedicalWebPage", "name": "Trimédoxime", "alternateName": "Trimedoxime", "url": "https://questionsmedicales.fr/mesh/D014289", "about": { "@type": "MedicalCondition", "name": "Trimédoxime", "code": { "@type": "MedicalCode", "code": "D014289", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.900" } } }, { "@type": "MedicalWebPage", "name": "Viologènes", "alternateName": "Viologens", "url": "https://questionsmedicales.fr/mesh/D014755", "about": { "@type": "MedicalCondition", "name": "Viologènes", "code": { "@type": "MedicalCode", "code": "D014755", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.925" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzyl viologène", "alternateName": "Benzyl Viologen", "url": "https://questionsmedicales.fr/mesh/D001594", "about": { "@type": "MedicalCondition", "name": "Benzyl viologène", "code": { "@type": "MedicalCode", "code": "D001594", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.925.100" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Composés de pyridinium", "alternateName": "Pyridinium Compounds", "code": { "@type": "MedicalCode", "code": "D011726", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sungwoo Hong", "url": "https://questionsmedicales.fr/author/Sungwoo%20Hong", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr." } }, { "@type": "Person", "name": "Werner Fudickar", "url": "https://questionsmedicales.fr/author/Werner%20Fudickar", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Potsdam, Potsdam, Germany." } }, { "@type": "Person", "name": "Torsten Linker", "url": "https://questionsmedicales.fr/author/Torsten%20Linker", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, University of Potsdam, Potsdam, Germany." } }, { "@type": "Person", "name": "Lihua Luo", "url": "https://questionsmedicales.fr/author/Lihua%20Luo", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China." } }, { "@type": "Person", "name": "Rui Sun", "url": "https://questionsmedicales.fr/author/Rui%20Sun", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.", "datePublished": "2022-10-17", "url": "https://questionsmedicales.fr/article/36251860", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13506129.2022.2131384" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.", "datePublished": "2024-09-13", "url": "https://questionsmedicales.fr/article/39346594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2024.1385089" } }, { "@type": "ScholarlyArticle", "name": "Reward network dysfunction is associated with cognitive impairment after stroke.", "datePublished": "2023-05-31", "url": "https://questionsmedicales.fr/article/37307650", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.nicl.2023.103446" } }, { "@type": "ScholarlyArticle", "name": "Predictors of cognitive dysfunction one-year post COVID-19.", "datePublished": "2023-01-05", "url": "https://questionsmedicales.fr/article/36603126", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1037/neu0000876" } }, { "@type": "ScholarlyArticle", "name": "Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.", "datePublished": "2022-12-07", "url": "https://questionsmedicales.fr/article/36729842", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/RHU.0000000000001888" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyridines", "item": "https://questionsmedicales.fr/mesh/D011725" }, { "@type": "ListItem", "position": 5, "name": "Composés de pyridinium", "item": "https://questionsmedicales.fr/mesh/D011726" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Composés de pyridinium - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Composés de pyridinium", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Composés de pyridinium", "description": "Comment diagnostiquer une intoxication aux composés de pyridinium ?\nQuels tests sont utilisés pour détecter les composés de pyridinium ?\nQuels symptômes indiquent une exposition aux pyridiniums ?\nLes tests urinaires peuvent-ils détecter les pyridiniums ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Composés de pyridinium", "description": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?\nLes composés de pyridinium provoquent-ils des effets neurologiques ?\nY a-t-il des symptômes cutanés associés aux pyridiniums ?\nLes symptômes varient-ils selon le type de pyridinium ?\nComment les symptômes évoluent-ils avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Composés de pyridinium", "description": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?\nLes formations sont-elles nécessaires pour manipuler des pyridiniums ?\nComment stocker les composés de pyridinium en toute sécurité ?\nLes fuites de pyridiniums peuvent-elles être évitées ?\nQuelles sont les recommandations pour les laboratoires ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Composés de pyridinium", "description": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?\nLes soins de soutien sont-ils nécessaires pour les patients exposés ?\nQuels antidotes sont utilisés contre les pyridiniums ?\nLa dialyse est-elle efficace pour éliminer les pyridiniums ?\nComment prévenir les complications lors du traitement ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Composés de pyridinium", "description": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?\nLes effets à long terme des pyridiniums sont-ils connus ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles être évitées ?\nQuels sont les signes d'alerte pour des complications graves ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Composés de pyridinium", "description": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?\nL'âge influence-t-il la sensibilité aux pyridiniums ?\nLes antécédents médicaux augmentent-ils le risque d'intoxication ?\nLes conditions environnementales jouent-elles un rôle ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Cognitive+Dysfunction&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication aux composés de pyridinium ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et des tests sanguins spécifiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour détecter les composés de pyridinium ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses chromatographiques et spectrométriques sont couramment utilisées." } }, { "@type": "Question", "name": "Quels symptômes indiquent une exposition aux pyridiniums ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques." } }, { "@type": "Question", "name": "Les tests urinaires peuvent-ils détecter les pyridiniums ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains tests urinaires peuvent révéler la présence de métabolites pyridiniques." } }, { "@type": "Question", "name": "Quelle est l'importance de l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux pyridiniums." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des douleurs abdominales, des vertiges et des troubles respiratoires." } }, { "@type": "Question", "name": "Les composés de pyridinium provoquent-ils des effets neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent causer des maux de tête, des convulsions et des troubles de la conscience." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés aux pyridiniums ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées et des irritations peuvent survenir après contact avec ces composés." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de pyridinium ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la structure chimique et de la dose." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver sans traitement approprié, nécessitant une intervention rapide." } }, { "@type": "Question", "name": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle lors de la manipulation de ces composés." } }, { "@type": "Question", "name": "Les formations sont-elles nécessaires pour manipuler des pyridiniums ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations sur la sécurité chimique sont essentielles pour les travailleurs exposés." } }, { "@type": "Question", "name": "Comment stocker les composés de pyridinium en toute sécurité ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les stocker dans des contenants hermétiques et étiquetés, à l'écart des sources de chaleur." } }, { "@type": "Question", "name": "Les fuites de pyridiniums peuvent-elles être évitées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en vérifiant régulièrement les équipements et en respectant les protocoles de sécurité." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour les laboratoires ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les laboratoires doivent suivre des protocoles stricts de manipulation et de stockage des pyridiniums." } }, { "@type": "Question", "name": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est la décontamination et l'administration d'antidotes spécifiques." } }, { "@type": "Question", "name": "Les soins de soutien sont-ils nécessaires pour les patients exposés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins de soutien, comme l'hydratation et la surveillance, sont souvent requis." } }, { "@type": "Question", "name": "Quels antidotes sont utilisés contre les pyridiniums ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des antidotes comme l'atropine peuvent être administrés pour contrer les effets toxiques." } }, { "@type": "Question", "name": "La dialyse est-elle efficace pour éliminer les pyridiniums ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La dialyse peut être envisagée dans les cas graves d'intoxication pour éliminer les toxines." } }, { "@type": "Question", "name": "Comment prévenir les complications lors du traitement ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance étroite et un traitement rapide des symptômes sont essentiels pour prévenir les complications." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des lésions organiques, des troubles neurologiques et respiratoires peuvent survenir." } }, { "@type": "Question", "name": "Les effets à long terme des pyridiniums sont-ils connus ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires chroniques." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications nécessitent une prise en charge médicale spécialisée et un suivi régulier." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une intervention rapide et un traitement approprié peuvent réduire le risque de complications." } }, { "@type": "Question", "name": "Quels sont les signes d'alerte pour des complications graves ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des difficultés respiratoires, des convulsions ou une confusion mentale doivent alerter." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en chimie, agriculture et industrie sont les plus exposés aux pyridiniums." } }, { "@type": "Question", "name": "L'âge influence-t-il la sensibilité aux pyridiniums ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées sont plus sensibles aux effets toxiques." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque d'intoxication ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les conditions environnementales jouent-elles un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conditions comme la chaleur ou l'humidité peuvent exacerber les effets des pyridiniums." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions médicamenteuses peuvent augmenter la toxicité des pyridiniums." } } ] } ] }

Sources (10000 au total)

Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant.

Cognitive dysfunction is part of the broad spectrum of clinical manifestations in older untreated hereditary transthyretin amyloidosis patients with peripheral polyneuropathy.... The objective of this study is to systematically explore cognitive dysfunction in ATTRV30M amyloidosis patients whose disease course was modified by liver transplant (LT).... A series of 269 carriers of TTRVal30Met mutation treated with LT underwent a neuropsychological assessment. Clinical charts were reviewed to identify focal neurological episodes (FNEs), cognitive comp... Cognitive dysfunction was identified in 35 patients (13%)-14 (5%) had mild and 21 (8%) had moderate dysfunction. In comparison to normal cognition, both mild and moderate cognitive dysfunction patient... Consistent with the natural history of the disease, older age and higher severity of the disease are significantly associated and potentially predictors of cognitive dysfunction in ATTRV30M patients t...

Risk factors for cognitive dysfunction amongst patients with cardiovascular diseases.

The impact of cardiovascular diseases on cognition raises important research questions. The study aimed to investigate the relationship between demographic data, cardiovascular diseases, kidney diseas... A cross-sectional study of patients with cardiovascular diseases was performed. The Montreal Cognitive Assessment (MoCA) was applied for cognitive evaluation. Based on MoCA three groups were defined: ... Of 628 patients, 55.2% had mild CD, and the mean age was 67.95 (SD 9.53) years. Cα and Mω were 0.7, indicating good internal consistency. We found a moderate positive correlation between depression an... Mild CD was the most common in patients with cardiovascular diseases. Older age, lower education, being a non-smoker, and renal dysfunction were risk factors for both mild and advanced CD. Female gend...

Predictors of cognitive dysfunction one-year post COVID-19.

(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitiv... One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Vis... Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acut... A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infe...

Cognitive Dysfunction Biomarkers in Patients With Rheumatoid Arthritis: A Systematic Review.

During the last years, a growing number of studies have investigated the link between cognitive dysfunction and rheumatoid arthritis (RA), highlighting the potential pathogenic role of several clinica... We performed a systematic review using PRISMA (Preferred Reported Items for Systematic Reviews and Meta-analysis) protocol. A systematic search was conducted in the PubMed/MEDLINE, EMBASE, LILACS, Sco... Five original studies were included, which provided data from 428 participants. Among plasma proteins, SHH was increased and TTR was reduced in patients with mild cognitive impairment; anti-myelin bas... Despite the relative scarcity of studies on this subject and the heterogeneity of results, we identified possible biomarkers for cognitive deficits in the RA population. Further longitudinal studies a...

Endothelial Dysfunction and Pre-Existing Cognitive Disorders in Stroke Patients.

The origin of pre-existing cognitive impairment in stroke patients remains controversial, with a vascular or a degenerative hypothesis.... To determine whether endothelial dysfunction is associated with pre-existing cognitive problems, lesion load and biological anomalies in stroke patients.... Patients originated from the prospective STROKDEM study. The baseline cognitive state, assessed using the IQ-CODE, and risk factors for stroke were recorded at inclusion. Patients with an IQ-CODE scor... A total of 86 patients were included (52 males; mean age 63.5 ± 11.5 years). Patients with abnormal RHI have hypertension or antihypertensive treatment more often. The baseline IQ-CODE was abnormal in... A vascular mechanism may be responsible for cognitive problems pre-existing stroke. The measurement of endothelial dysfunction after stroke could become an important element of follow-up, providing an...

Cognitive Dysfunction in Heart Failure: Pathophysiology and Implications for Patient Management.

There is increasing recognition of the prevalence and impact of cognitive dysfunction (CD) in heart failure (HF) patients. This contemporary review appraises the evidence for epidemiological associati... CD disproportionately affects heart failure patients, even accounting for known comorbid risk factors, and this may extend to subclinical left ventricular dysfunction. Neuroimaging studies now provide...

Frequency and risk factors for cognitive dysfunction in peritoneal dialysis patients.

There is limited data on cognition in patients undergoing peritoneal dialysis (PD). We assessed prevalence and associated risk factors of neurocognitive impairment (NCI) in PD patients.... A cross-sectional cohort study of 149 PD patients at a single centre between 2016 and 2020 who underwent neurocognitive screening at defined intervals by Addenbrooke's Cognitive Examination - Revised ... Patients on PD performed poorly in ACE-R screening compared to population norms, with discrepancy in all cognitive domains. In patients without CVD, attention and language domains were comparable to n... Patients on PD have higher prevalence of NCI than the general population, primarily with impairments in memory, fluency and visuospatial reasoning. CVD confers poorer performance in attention and lang...